- Home
- THAR vs ADIL Comparison
THAR vs ADIL Comparison
Compare THAR & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- ADIL
- Stock Information
- Founded
- THAR 2017
- ADIL 2010
- Country
- THAR United States
- ADIL United States
- Employees
- THAR N/A
- ADIL N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- ADIL Health Care
- Exchange
- THAR Nasdaq
- ADIL Nasdaq
- Market Cap
- THAR 5.5M
- ADIL 6.0M
- IPO Year
- THAR 2022
- ADIL 2018
- Fundamental
- Price
- THAR $1.35
- ADIL $0.39
- Analyst Decision
- THAR Strong Buy
- ADIL Strong Buy
- Analyst Count
- THAR 1
- ADIL 1
- Target Price
- THAR $17.00
- ADIL $8.00
- AVG Volume (30 Days)
- THAR 119.3K
- ADIL 4.0M
- Earning Date
- THAR 08-14-2025
- ADIL 08-13-2025
- Dividend Yield
- THAR N/A
- ADIL N/A
- EPS Growth
- THAR N/A
- ADIL N/A
- EPS
- THAR N/A
- ADIL N/A
- Revenue
- THAR N/A
- ADIL N/A
- Revenue This Year
- THAR N/A
- ADIL N/A
- Revenue Next Year
- THAR N/A
- ADIL N/A
- P/E Ratio
- THAR N/A
- ADIL N/A
- Revenue Growth
- THAR N/A
- ADIL N/A
- 52 Week Low
- THAR $0.95
- ADIL $0.22
- 52 Week High
- THAR $6.39
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- THAR 46.35
- ADIL 45.40
- Support Level
- THAR $1.15
- ADIL $0.38
- Resistance Level
- THAR $1.66
- ADIL $0.42
- Average True Range (ATR)
- THAR 0.12
- ADIL 0.06
- MACD
- THAR 0.01
- ADIL -0.01
- Stochastic Oscillator
- THAR 39.22
- ADIL 10.73
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.